Literature DB >> 11413516

Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy.

L Krishnan1, A L Stanton, C A Collins, V E Liston, W R Jewell.   

Abstract

BACKGROUND: Treatment-related factors that influence quality of life (QOL) for women who are diagnosed with breast carcinoma require study. This study was designed to examine the convergent validity of objective and subjective indices of cosmetic and functional status after patients undergo breast-conserving treatment (BCT) and to test the relations of the objective indicators with QOL.
METHODS: Women (n = 54 patients) who had received BCT and radiotherapy for Stage 0-II disease for whom the diagnosis duration ranged from 9 months to 18 years completed assessments of background information, perceived cosmetic and functional outcomes, and QOL. They also were administered a clinical breast examination, including objective ratings of arm edema and breast cosmesis. The patients were a subsample from the study reported by the authors in an accompanying article that is presented in this issue.
RESULTS: The findings revealed positive cosmetic and functional treatment outcomes, such that 82% of patients had no or minimal arm edema, and 70% of patients evidenced good or excellent cosmetic results. Convergent validity was demonstrated for the objective and subjective assessments of cosmetic and functional treatment outcomes. In addition, women who had more arm edema reported poorer QOL with regard to depressive symptoms (P < 0.05) and fear of disease recurrence (P < 0.05).
CONCLUSIONS: The findings from this study and those reported in the accompanying article reveal that functional treatment outcomes, such as arm edema and breast specific pain, are important correlates of QOL even many years after patients undergo BCT and radiotherapy. Both subjective and objective indicators of treatment outcomes are useful predictors of QOL. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11413516

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies.

Authors:  Sébastien Simard; Belinda Thewes; Gerry Humphris; Mélanie Dixon; Ceara Hayden; Shab Mireskandari; Gozde Ozakinci
Journal:  J Cancer Surviv       Date:  2013-03-10       Impact factor: 4.442

2.  Patient-reported Quality of Life and Satisfaction With Cosmetic Outcomes After Breast Conservation and Mastectomy With and Without Reconstruction: Results of a Survey of Breast Cancer Survivors.

Authors:  Reshma Jagsi; Yun Li; Monica Morrow; Nancy Janz; Amy Alderman; John Graff; Ann Hamilton; Steven Katz; Sarah Hawley
Journal:  Ann Surg       Date:  2015-06       Impact factor: 12.969

3.  Cancer patient and survivor research from the cancer information service research consortium: a preview of three large randomized trials and initial lessons learned.

Authors:  Alfred C Marcus; Michael A Diefenbach; Annette L Stanton; Suzanne M Miller; Linda Fleisher; Peter C Raich; Marion E Morra; Rosemarie Slevin Perocchia; Zung Vu Tran; Mary Anne Bright
Journal:  J Health Commun       Date:  2013-02-28

4.  Depression and anxiety levels in woman under follow-up for breast cancer: relationship to coping with cancer and quality of life.

Authors:  Omur Karakoyun-Celik; Ilknur Gorken; Sema Sahin; Esmahan Orcin; Hilmi Alanyali; Munir Kinay
Journal:  Med Oncol       Date:  2009-02-19       Impact factor: 3.064

5.  Automated microscopy to evaluate surgical specimens via touch prep in breast cancer.

Authors:  Maria Jose Cortes-Mateos; David Martin; Sergio Sandoval; Manuel E Ruidiaz; Davorka Messmer; Jessica Wang-Rodriguez; William Trogler; Andrew C Kummel; Sarah L Blair
Journal:  Ann Surg Oncol       Date:  2009-01-10       Impact factor: 5.344

6.  Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.

Authors:  Gary M Freedman; Penny R Anderson; Richard J Bleicher; Samuel Litwin; Tianyu Li; Ramona F Swaby; Chang-Ming Charlie Ma; Jinsheng Li; Elin R Sigurdson; Deborah Watkins-Bruner; Monica Morrow; Lori J Goldstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-12       Impact factor: 7.038

7.  Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.

Authors:  Julius K Weng; Xiudong Lei; Pamela Schlembach; Elizabeth S Bloom; Simona F Shaitelman; Isidora Y Arzu; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-13       Impact factor: 8.013

8.  Quality of life determinants in women with breast cancer undergoing treatment with curative intent.

Authors:  Manoj Pandey; Bejoy Cherian Thomas; Padmakumar SreeRekha; Kunnambath Ramdas; Kuttan Ratheesan; Sankarannair Parameswaran; Beela S Mathew; Balakrishnan Rajan
Journal:  World J Surg Oncol       Date:  2005-09-27       Impact factor: 2.754

9.  Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A.

Authors:  Grit Welzel; Angela Boch; Elena Sperk; Frank Hofmann; Uta Kraus-Tiefenbacher; Axel Gerhardt; Marc Suetterlin; Frederik Wenz
Journal:  Radiat Oncol       Date:  2013-01-07       Impact factor: 3.481

10.  TGF-β1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT).

Authors:  Sandra D Scherer; Jochen Bauer; Anja Schmaus; Christian Neumaier; Carsten Herskind; Marlon R Veldwijk; Frederik Wenz; Jonathan P Sleeman
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.